|
🐜
|
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
15 auth.
M. Passini,
J. Bu,
A. Richards,
Cathrine Kinnecom,
S. Sardi,
L. Stanek,
Y. Hua,
F. Rigo,
J. Matson,
G. Hung,
...
E. Kaye,
L. Shihabuddin,
A. Krainer,
C. Bennett,
Seng H. Cheng
|
8 |
2011 |
8
🐜
|
|
🐜
|
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
14 auth.
F. Rigo,
S. Chun,
D. Norris,
G. Hung,
Sam Lee,
J. Matson,
R. Fey,
H. Gaus,
Y. Hua,
J. Grundy,
...
A. Krainer,
S. Henry,
C. Bennett,
New York.
|
7 |
2014 |
7
🐜
|
|
🐜
|
Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
10 auth.
R. Geary,
R. Yu,
Tanya A. Watanabe,
S. Henry,
G. Hardee,
A. Chappell,
...
J. Matson,
H. Sasmor,
L. Cummins,
A. Levin
|
7 |
2003 |
7
🐜
|
|
🐜
|
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
13 auth.
E. Ackermann,
Shuling Guo,
M. Benson,
S. Booten,
S. Freier,
S. Hughes,
Tae-Won Kim,
T. Jesse Kwoh,
J. Matson,
D. Norris,
...
R. Yu,
A. Watt,
B. Monia
|
6 |
2016 |
6
🐜
|
|
🐜
|
Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment.
22 auth.
Daniel M. Ramos,
C. d’Ydewalle,
V. Gabbeta,
A. Dakka,
S. Klein,
Daniel A. Norris,
J. Matson,
Shannon J. Taylor,
P. Zaworski,
Thomas W. Prior,
...
Pamela J. Snyder,
D. Valdivia,
Christine L. Hatem,
Ian G. Waters,
N. Gupte,
Kathryn J. Swoboda,
F. Rigo,
C. F. Bennett,
Nikolai Naryshkin,
S. Paushkin,
Thomas O Crawford,
Charlotte J. Sumner
|
6 |
2019 |
6
🐜
|
|
🐜
|
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
9 auth.
R. Yu,
K. Lemonidis,
M. Graham,
J. Matson,
R. Crooke,
D. Tribble,
...
M. Wedel,
A. Levin,
R. Geary
|
6 |
2009 |
6
🐜
|
|
🐜
|
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
7 auth.
R. Yu,
R. Geary,
D. Monteith,
J. Matson,
L. Truong,
J. Fitchett,
...
A. Levin
|
6 |
2004 |
6
🐜
|
|
🐜
|
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
7 auth.
R. Geary,
E. Wancewicz,
J. Matson,
Megan Pearce,
A. Siwkowski,
E. Swayze,
...
F. Bennett
|
6 |
2009 |
6
🐜
|
|
🐜
|
The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
14 auth.
P. Jafar‐nejad,
Berit E. Powers,
Armand Soriano,
H. Zhao,
D. Norris,
J. Matson,
Bea DeBrosse-Serra,
Jamie Watson,
P. Narayanan,
S. Chun,
...
C. Mazur,
H. Kordasiewicz,
E. Swayze,
F. Rigo
|
6 |
2020 |
6
🐜
|
|
🐜
|
Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.
24 auth.
C. Mazur,
Berit E. Powers,
K. Zasadny,
Jenna M. Sullivan,
H. Dimant,
F. Kamme,
J. Hesterman,
J. Matson,
Michael E. Oestergaard,
Marc E. Seaman,
...
Robert W Holt,
Mohammed Q. Qutaish,
Ildiko Polyak,
Richard Coelho,
V. Gottumukkala,
C. Gaut,
M. Berridge,
Nazira J. Albargothy,
L. Kelly,
R. Carare,
J. Hoppin,
H. Kordasiewicz,
E. Swayze,
A. Verma
|
6 |
2019 |
6
🐜
|
